Tailored cell-based bioassay or potency assays for biologics and biosimilars to meet the requirements of ICH Q6B and Good Manufacturing Practice (GMP)

GMP cell-based potency testing quantitatively determines the biological activity of a biopharmaceutical. Measurement of potency plays an essential role in quality control, GMP product release and biopharmaceutical stability testing for both drug product and drug substance. Biological activity or potency is a critical quality attribute that often faces increased scrutiny by regulators over other types of test. The method/type of potency test employed is specific to the mechanism of action (MOA) of the biologic being studied and to meet the requirements of regulatory submissions, the potency assay should be validated to ICH Q2 (R2) standards.
 
Our potency testing experts offer tailored bioassay method development, method transfer and method validation to ICH Q2 (R2) standards via an array techniques including cell-based assays, ligand and receptor binding assays and flexible multiple assay approaches. Through this tailored approach, we maximize the efficiency of study design bringing cost-efficiencies and time-saving benefits. We also conduct routine potency release testing to GMP standards. Our experts work closely with you to provide a fully validated potency assay for your biologic, suitable for regulatory submission, which will perform reproducibly throughout the whole drug development process.
 
Cell-based Assays 
Cell-based assays determine the relative potency of a product by comparing the biological response/activity, related to its mode of action, with a control/reference preparation (USP, WHO or in-house reference standard). This allows the product’s efficacy and ability to achieve a defined biological effect to be quantified. We apply a range of cell-based assay models to characterize recombinant proteins/ monoclonal antibodies:
  • Cell migration assays 
  • Cell signalling assays 
  • Cell proliferation/inhibition assays
  • Binding and/or competitive assays

Ligand and Receptor Binding Assays
Enzyme Linked Immuno-Sorbent Assays (ELISA) allows direct measurement of the biologic’s affinity to its target with typically, a robust performance.

Flexible, Multiple Assay Approaches for Monoclonal Antibodies
For products which have multiple MOAs, multiple assays may be needed to sufficiently demonstrate product efficacy as well as lot-to-lot comparability. We apply flexible approaches from an array of cell based assay platforms/models, as well as physico-chemical assays to designing potency assays for monoclonal antibodies and/or antibody drug conjugates (ADC’s) in order to assess their multiple MOA. 

GMP Cell-based Assays or Potency Assay Applications
We apply phase-appropriate potency testing to wide array of biologic products including biosimilars, peptides, monoclonal antibodies, growth factors and cytokines and applications, such as biopharmaceutical stability testing and biologic drug product release testing

Our expertise in complex method development and validation for potency or biologic activity assessment can give you detailed insight into your biologic, helping to accelerate your development process. We can additionally provide extensive protein structure analysis from the primary structure through to higher-order structure, post-translational modifications and glycosylation studies. Our protein physicochemical property determination services include molecular weight and electrophoretic, chromatographic and spectroscopic profiles. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards. 

Need help or have a question?

Related Links

Cell based potency testing for biopharmceuticals

2024 Hybrid European Bioassay Conference (BEBPA) 

Meet Intertek's experts at BEBPA

Discuss how we can assist you with your bioanalytical needs. We provide customized strategic and efficient bioanalytical programs based on therapeutic needs, including cell-based assay and biomarker solutions.

Contact us now to arrange a meeting.

Where? Prague, Czech Republic
When? 25-27 September 2024

The Inhaled and Nasal Biologics DNA forum logo in white and yellow font against a dark turquoise backgrouns

3rd Annual Inhaled & Nasal Biologics | DNA Forum

26-27 September 2024
Cambridge, UK 


Join us for a ground-breaking and insightful forum on inhaled and nasal biologics development: Two days of cutting-edge talks and networking opportunities with leaders in this complex area of inhaled medication and inhaled vaccine development.
LEARN MORE & REGISTER

Contact Intertek